Lecalcif (Colecalciferol)

After ingestion, colecalciferol is converted in the liver to 25‑hydroxyvitamin D and then in the kidney to the active hormone 1,25‑dihydroxyvitamin D. This active form binds the nuclear vitamin D receptor, stimulating production of calcium‑binding proteins that increase intestinal calcium and phosphate uptake.

The prescribed dose of Lecalcif is individualized by a healthcare professional based on the patient’s serum vitamin D level, age, weight, and clinical condition. Dosage may range from low maintenance to higher therapeutic amounts, and the prescriber determines the appropriate regimen.

Safety data for colecalciferol in pregnancy and lactation are limited. It should only be used when the potential benefit outweighs any possible risk, and under medical supervision. Pregnant or nursing individuals should consult their healthcare provider before starting Lecalcif.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lecalcif provides colecalciferol, the natural form of vitamin D3, which is generally preferred over vitamin D2 (ergocalciferol) due to higher potency and longer duration of action. Compared with prescription calcitriol, colecalciferol requires metabolic activation, offering a safer profile for routine supplementation.

Store Lecalcif at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Lecalcif is taken orally, usually with or without food, as directed by a healthcare professional. The tablet or capsule should be swallowed whole with a glass of water. Patients should follow the prescriber’s instructions regarding timing and frequency.

The most serious risk is hypercalcemia, which can cause nausea, vomiting, weakness, and cardiac arrhythmias. Severe hypercalcemia may lead to kidney stones or renal impairment. Prompt monitoring of serum calcium and vitamin D levels helps mitigate these risks.

Individuals with known hypersensitivity to colecalciferol or any excipients, patients with hypercalcemia, severe renal disease, or granulomatous disorders such as sarcoidosis should avoid Lecalcif unless a physician determines it is safe. Consultation with a healthcare provider is essential before initiating therapy.